Eli Lilly's Obesity Pill: Trial Results, Competition, and Valuation with Geoff Meacham

Eli Lilly's Obesity Pill Trial Success

• 📈 Eli Lilly's stock surged, leading the S&P 500, after their obesity pill successfully cleared another late-stage trial.
• 🎯 Patients with type 2 diabetes and obesity lost an average of 10.5% of their body weight over 72 weeks on the highest dose.
• ✅ The results are considered derisking, as this is the third trial, with over 5,000 patients treated and good safety/tolerability reported.

Oral vs. Injectable GLP-1 Drugs

• 💊 The pill version of the GLP-1 weight loss drug is super important, but not the sole solution.
• 💉 While injectables will still have a place, the market may settle around a 60/40 split favoring injectables or oral administration.
• ⚖️ Oral administration is expected to be crucial, potentially for patients who are more overweight than obese, or for temporary use.

Stock Valuation and Growth Potential

• 💰 Previously, a 50x multiple was a concern, but the current valuation of around 25x next year's numbers is more manageable.
• 🚀 Despite past stock pressure due to fears of policy changes and being overowned, Eli Lilly is seen as having no better growth story in healthcare over the next 12-24 months.
• ⚠️ As fears subside, the stock is expected to become safer to own, with Eli Lilly positioned as the best grower in the space.

Side Effects and Future Indications

• ⚠️ A 10% discontinuation rate due to side effects across trials is considered compelling from a commercial perspective, with no egregious safety events reported.
• 🚀 The drug, Orforglipron, is an oral option that could be used for short-term weight loss before events or as maintenance therapy after using injectable drugs.
• ⚖️ Data on its effectiveness as maintenance therapy will be available in Q1 next year, which could drive significant sales and value, although weight regain after stopping the drug is a possibility.